SingleMetabolic / GLP-1

HGH Fragment 176-191 5mg

A truncated C-terminal human growth hormone peptide investigated in laboratory settings for lipolytic signaling without glycemic perturbation.

Mechanism

Stimulates hormone-sensitive lipase and inhibits acetyl-CoA carboxylase within adipocytes to drive triglyceride hydrolysis without altering serum glucose or IGF-1.

Dosing

Standard laboratory conventions document a starting subcutaneous protocol of 250 mcg once or twice daily while fasted.

Reconstitution

Mix with 2 mL bacteriostatic water to achieve a final working concentration of 2.5 mg/mL.

Storage

Store the reconstituted solution refrigerated at 2 to 8 degrees Celsius protected from light, avoiding freezing and rough agitation.

Mix & measure HGH Fragment 176-191 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure HGH Fragment 176-191 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration2.50mg/mL

Draw volume0.100mL

On the syringe10.0units

Total doses in vial: 20.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Initial / Starting	250 mcg (Once or twice daily, fasted)	10 units (0.10 mL)
Intermediate	300 mcg (Once or twice daily, fasted)	12 units (0.12 mL)
Moderate	400 mcg (Once or twice daily, fasted)	16 units (0.16 mL)
Upper Range	500 mcg (Once or twice daily, fasted)	20 units (0.20 mL)

Reconstitution Steps

1
Disinfect the rubber stoppers of both the peptide vial and the bacteriostatic water container with fresh alcohol swabs.
2
Draw 2 mL of bacteriostatic water into a sterile mixing syringe.
3
Insert the needle and trickle the diluent slowly down the glass wall of the vial to prevent clumping of the delicate peptide powder.
4
Permit the vial to rest briefly, then gently roll or swirl between your hands until completely dissolved without shaking.
5
Visually verify that the solution is transparent and free of precipitates before transferring to refrigerated storage at 2 to 8 °C.

Supplies Needed

Peptide Vial

Lyophilized research vial containing 5 mg of purified HGH Fragment 176-191.

Insulin Syringes (U-100)

Precision measuring instruments calibrated with 100 units per mL for precise microgram draws.

Bacteriostatic Water

Sterile diluent preserved with 0.9% benzyl alcohol used to reconstitute 2 mL per vial.

Alcohol Swabs

Sterile isopropyl alcohol pads used to decontaminate rubber stoppers prior to puncturing.

Why researchers study it

Differential pharmacology versus the modified analog AOD-9604

Preclinical adipose tissue lipolysis and hormone-sensitive lipase induction

Absence of IGF-1 mediated growth effects and glycemic impairment

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

HGH Fragment 176-191 represents an isolated 16-amino-acid synthetic domain corresponding to the carboxyl terminus of native human somatotropin. Originally isolated during basic endocrinology research attempting to untangle growth stimulation from metabolic effects, this peptide models the isolated fat-clearing action of growth hormone without activating systemic IGF-1 signaling cascades. Laboratory models examine this truncated peptide for its capacity to stimulate lipid mobilization and reduce adipocyte volume without the diabetogenic outcomes, fluid retention, or insulin resistance typically seen with whole-chain human growth hormone administration. While it exhibits robust lipolytic activity in rodent trials, its physiological distinction from the modified variant AOD-9604 remains a critical factor in comparative peptide research. Because this peptide lacks regulatory approval for human clinical therapy, literature values are derived primarily from preclinical animal work and published grey-market benchmarks. Research environments utilize these standardized guidelines to ensure accurate reconstitution, measurement, and experimental handling.

References

1.Ng et al., Journal of Molecular Endocrinology, 2000 — C-terminal hGH domain (residues 177-191) lipolytic actions without diabetogenic effects in Zucker rats
2.Heffernan et al., Endocrinology, 2001 — Lipid metabolism and beta-3 adrenergic receptor involvement of hGH and lipolytic fragments in obese mice
3.Wilding, Current Opinion in Investigational Drugs, 2004 — Clinical overview of the related modified analog AOD-9604 in obesity trials
4.Cox et al., Drug Testing and Analysis, 2014 — Structural definition, sports prohibition, and analytical urine detection of AOD9604
5.Orlovius et al., Drug Testing and Analysis, 2013 — Doping analysis and interaction of hGH C-terminal fragments with isoform immunoassay